Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis
Open Access
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 46, 102572
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Merck KGaA
- Bayer HealthCare
- Novartis
- Bayer Schering
This publication has 17 references indexed in Scilit:
- Cladribine — an old newcomer for pulsed immune reconstitution in MSNature Reviews Neurology, 2017
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyMultiple Sclerosis Journal, 2017
- Both cladribine and alemtuzumab may effect MS via B-cell depletionNeurology Neuroimmunology & Neuroinflammation, 2017
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trialThe Lancet Neurology, 2014
- Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyJournal of the Neurological Sciences, 2013
- MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY studyJournal of Neurology, 2012
- Cladribine tablets for relapsing–remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY studyMultiple Sclerosis and Related Disorders, 2012
- Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisThe Lancet Neurology, 2011
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Comparative analysis of two ratesStatistics in Medicine, 1985